 Treatment systemic vasculitis pooled intravenous immunoglobulin therapeutic effect course high-dose intravenous immunoglobulin IVIg disease activity antineutrophil cytoplasm antibodies ANCA patients systemic vasculitis active disease conventional immunosuppression treatment clinical improvement transient fall ANCA concentrations mean pre-treatment values follow-up C-reactive protein concentration IVIg useful therapeutic effect adverse reaction